The relationship between the Tirzepatida and cardiovascular health it gained even more attention after the publication of the results of the SURPASS-CVOT, a large study that assessed people with type 2 diabetes and atherosclerotic cardiovascular disease is already established.
Until recently, much of the evidence on the cardiovascular health came from changes in risk factors, such as weight, blood pressure, blood sugar, and triglycerides. Right now, there are data from a study designed to observe the cardiovascular events important to them.
The findings are relevant to you, but you need to be interpreted without the hype. The Tirzepatida should not be presented as if the “protect your heart” in a way guaranteed for anyone. The benefit depends on the clinical profile, as well as different studies to answer the different questions.
In this article, you are going to understand what is already known about the Tirzepatida and cardiovascular healthincluding blood pressure, weight, cholesterol, diabetes, and the main results of the SURPASS-CVOT.
- Important: this content is informative and it does not replace evaluation by a doctor. People with heart disease, high blood pressure, diabetes or the use of multiple medications, need for follow-up have been added.
Why is obesity and diabetes affect the heart?
Obesity and type 2 diabetes is strongly associated with the increased risk of heart attack, stroke, and other cardiovascular diseases.
This is because these terms often appear in various factors such as:
- high blood pressure;
- resistance to insulin;
- the glucose is high;
- tg high
- changes in serum cholesterol;
- inflammation, chronic
- an excess of visceral fat.
For this reason, to improve cardiovascular health don't depend on a single number. The risk is the result of a combination of several factors, from time to time.
The Fda points out that obesity may increase the risk of type 2 diabetes, and cardiovascular disease, and other complications.
How to Tirzepatida influence factors for cardiovascular disease?
The Tirzepatida acts on the receptors for GIP and GLP-1, and it can produce significant changes in the body's metabolism.
The effects described are the following:
- the reduction of the weight of the body;
- the improved control of blood glucose levels;
- the improvement of insulin sensitivity;
- the reduction of the intake of food.
- the greater abundance.
These changes may indirectly influence the cardiovascular healthespecially when a person has obesity, hypertension, dyslipidemia, or type 2 diabetes.
But to improve, risk factors, it is not exactly the same thing, to prove that the reduction of heart attack or STROKE. For this reason, studies are needed on specific cardiovascular endpoints.
What is the SURPASS-CVOT?
The SURPASS-CVOT was a large clinical trial designed to assess the outcomes of cardiovascular disease in the Tirzepatida in people with type 2 diabetes and atherosclerotic cardiovascular disease.
The study compared the Tirzepatida with dulaglutida, an agonist of the GLP-1 that is already in possession of evidence of benefit to patients.
More than 13 thousand people have been randomly assigned.
The outcome was the principal has put together three events
- death due to cardiovascular;
- myocardial infarction;
- a cerebral vascular accident.
This is the kind of outcome was the composite is widely used in the study cardiovascular health because it brings together clinical events are of great importance.
What did the study find?
The SURPASS-CVOT, and the outcome of cardiovascular episodes have occurred in:
- 12,2% of the participants, and are treated with Tirzepatida;
- 13,1% of those treated with dulaglutida.
The results showed that the Tirzepatida was not less than the dulaglutida the combined risk of cardiovascular death, heart attack or STROKE.
This means that, within the range statistic, as defined by the study, it's Tirzepatida not had a worse performance than in the comparison.
This result is important for the cardiovascular healthmainly because of the study population had atherosclerotic disease, and therefore, the risk is high.
The Tirzepatida was higher than that dulaglutida?
By no means is statistically proven, to the outcome of the primary.
The hazard ratio was 0,92with a confidence interval of the 0,83 to 1,01.
The study has reached the criterion of non-inferiority, but it did not reach the threshold of statistical set, to demonstrate the superiority of the.
It is of fundamental importance.
It would not be right to turn the result into a statement such as:
“The Tirzepatida it reduces the heart is more than a dulaglutida.”
What the study found was that it was not the less on the outcome of cardio-core.
Then, the result is positive?
Yes, especially from the point of view of the security of cardiovascular disease.
Prior to a study of this size, it was of interest to confirm whether the effects of the Tirzepatida weight, and glucose were also consistent with the results of cardiovascular insurance in high-risk patients.
The SURPASS-CVOT have provided evidence of a robust than that in the population, and the drug had a cardiovascular performance is comparable to that of the dulaglutida.
It strengthens the body of evidence on the cardiovascular healthbut it does not mean that all people will experience the same reduction in the risk of an individual.
Tirzepatida reduce high blood pressure?
Studies in people with obesity showed a reduction in blood pressure throughout treatment.
A sub to the SURMOUNT-1 was used for monitoring the outpatient clinic for 24 hours to assess the blood pressure in participants with a BMI equal to or greater than 27 kg/m2).
The researchers observed a significant reduction in systolic blood pressure for 24 hours in the groups treated with Tirzepatida compared with placebo.
Blood pressure is one of the main components of the cardiovascular health, and the reductions are sustained, they may be clinically important in people with high blood pressure.
Weight loss, explains some of the reduction in the pressure ...
Most likely, yes.
Weight loss tends to be associated with a reduction in blood pressure in many people.
How to Tirzepatida can produce significant decreases in weight, a part of the observed effect of the pressure is likely related to the reduction of fat.
In addition, it improves insulin sensitivity and other metabolic changes can all contribute to.
This is to show you how cardiovascular health and weight control are connected, but they are not exactly the same thing.
And high cholesterol?
The Tirzepatida it can improve certain parameters of the lipid profile, especially triglycerides, and other markers cardiometabólicos.
At the SURMOUNT-1, there have been large improvements in various measures of cardiometabólicas. Further analysis also found a reduction in the risk of cardiovascular atherosclerotic estimated to be among the participants were obese or overweight.
However, it is important not to conclude that Tirzepatida replace the drugs that are specific for the body.
In those with LDL cholesterol in high-and cardio-vascular disease is established, statins and other treatments can be necessary to protect the cardiovascular health.
The Tirzepatida reduce LDL cholesterol?
The data do not support the idea that the Tirzepatida in a lowering LDL cholesterol.
For a discussion of the published in the The New England Journal of Medicine after you SURPASS-CVOT pointed out that, in spite of the increased weight loss and improved glycemic control, there has not been a material reduction in the LDL cholesterol in comparison with the dulaglutida.
This raises an important idea:
to improve the weight, and glucose, it does not eliminate the need to deal with each risk factor separately.
To cardiovascular healthmany people are still in need of the control-specific LDL cholesterol, blood pressure, cigarette smoking, and other factors.
Triglycerides can we improve it?
Yes.
The reduction in weight and improvement in metabolism seen with Tirzepatida often are accompanied by improvement in triglycerides, and other factors cardiometabólicos.
This effect is relevant, because the triglyceride to high, tend to appear together, and insulin resistance, abdominal obesity, and type 2 diabetes.
Even so, the goal of the clinical shouldn't be looking for just one marker alone.
To cardiovascular health it depends on the set of risk factors.
Diabetes and the heart are closely related to one another?
Yes.
People with type 2 diabetes have an increased risk of cardiovascular disease.
The glucose is high, over time it can contribute to the vascular lesion, but the risk is also affected by the pressure, cholesterol, kidney function, body weight, and smoking cessation.
For this reason, and the modern treatment of diabetes does not seek to reduce hb glicada.
It also seeks to reduce infection and protect the body.
In this context, data on cardiovascular disease in the Tirzepatida to help you better understand your role in the care of people with type 2 diabetes and a high risk of cardiovascular health has been compromised.
Weight loss by itself, it helps the heart.
Losing excess weight can improve a number of factors that are associated with the risk of cardiovascular disease.
Among the changes are the following:
- the reduction in blood pressure;
- the improvement of glucose;
- the reduction of the tg;
- less visceral fat;
- the improvement of the mobility.
- the improvement of the conditions related to the lot.
At the SURMOUNT-1, the participants, and are treated with Tirzepatida showed significant reductions in weight and improvements to various factors, cardiometabólicos.
This helps to explain why the cardiovascular health you can improve on, even prior to these events, such as heart attack or STROKE.
Visceral fat doesn't matter the risk of heart disease?
Yes.
Visceral fat is located around the organs, and has a strong association with insulin resistance and the risk of cardiometabólico.
Studies of the composition of the body, with Tirzepatida also showed significant reductions in the fat stomach.
The decrease in fat can be one of the pieces that you connect to a loss of weight, improved metabolism, and cardiovascular health.
But no single measure replaces the evaluation of the overall risk.
High blood pressure can improve a non-stop drug?
It can happen to the pressure decrease with weight loss, but it does not mean that anti-hypertensive medications need to be hung up automatically.
If treatment is to produce a large reduction in the weight and pressure, some people may need adjustment of your dose.
This should be done by a professional, be responsible.
An excessive loss of pressure can cause the following:
- shortness of breath;
- weakness;
- feeling light-headed;
- light-headed.
The Fda include low blood pressure, as between the events identified in the information security Tirzepatida for weight control.
So, keep up the pressure, it is part of an approach is safe and secure cardiovascular health.
Tirzepatida replace the statin?
No.
If a person is an indication for statin for elevated LDL, elevated diabetes, coronary heart disease, or other reason, you can start Tirzepatida don't automatically delete it.
The two therapies have different goals.
The Tirzepatida it acts primarily on the control of blood glucose levels, body weight, and the mechanisms of metabolism.
Statins act directly on the reduction of low density lipoprotein cholesterol, and are used specifically to reduce the risk of cardiovascular disease in the indicated groups.
Take care of your cardiovascular health generally, it involves combining different strategies, depending on the risk associated with each individual.
Tirzepatida replace a remedy for stress?
Also, it does not automatically.
The loss of weight can improve the pressure on, but you have hypertension you need to continue to be kept under review.
Some people might be able to reduce the medication over time, and others will continue to use them.
The decision is dependent on the measurements of pressure, symptoms, renal function, and history of cardiovascular disease.
Adjust anti-hypertensive medication on their own.
The exercise continues this important?
Yes.
The medicine is not a substitute for physical activity.
Exercise can help to:
- to improve cardiorespiratory conditioning;
- reduce blood pressure;
- to improve the sensitivity to insulin;
- to preserve muscle mass;
- to increase the functionality;
- assist in the maintenance of body weight.
These benefits are additional to the pharmacological effects.
To cardiovascular healtha routine of physical activity, adequate, it continues to be one of the main ways to prevent them.
The power even to do about it?
A lot.
A drug can decrease the appetite, and to facilitate the reduction of energy intake, but the quality of the food continues to influence the pressure, cholesterol, glucose, and nutrient intake.
A diet that is favourable to the heart tends to prioritise:
- fruit;
- vegetables,
- the pulses;
- whole-grain;
- suitable proteins;
- sources of unsaturated fats;
- lower excess sodium;
- less frequent use of ultraprocessados.
There is no need in a power supply is perfect.
The goal is to build a sustainable standard, which is a complement to the treatment of the cardiovascular health.
Is estimated to get into that discussion?
Yes.
With the development of obstructive sleep apnea is associated with a higher risk of high blood pressure, and cardiovascular disease.
Obesity is one of the major factors that are associated with the skin.
The indication of the brazilian Tirzepatida for the control of chronic weight includes the adults were overweight and at least one condition related to your weight. The Fda cites the examples, hypertension, dyslipidemia, obstructive sleep apnea and cardiovascular disease.
For this reason, weight loss, and improvement of the conditions attached to them could contribute to an overall profile of the cardiovascular health the most favorable.
Tirzepatida prevent heart attack in people without diabetes?
We can not generalize in this way.
The SURPASS-CVOT studied in people with:
- diabetes, type 2 diabetes.
- atherosclerotic cardiovascular disease is already established.
This means that its results are not to be automatically applied to a young person, with no diabetes and no cardiovascular disease.
Studies in obesity have shown improvement in several risk factors, but the risk factors and clinical events are the outcomes are different.
To claim direct benefit in the prevention of stroke in other populations, we need to evidence specific to it.
Those who took part in the SURPASS-CVOT?
The participants were, on average, about 64.
All had type 2 diabetes and atherosclerotic cardiovascular disease.
The mean duration of diabetes was approximately 15 years ago.
Therefore, it is a population with high cardiovascular risk.
It is important for the interpretation of the results cardiovascular health.
In a study carried out in the group replies to a specific question: how does the Tirzepatida if you like the dulaglutida in people who already have heart disease?
The side effects were for you.
The SURPASS-CVOT, the overall incidence of adverse events was similar between the two groups, even though the events of the gastro-intestinal they have been more frequent with a Tirzepatida.
This is in line with the profile of the already well-known of the medicinal product.
Nausea, diarrhea, vomiting, and constipation are among the effects in the gastro-intestinal's most well-known.
These symptoms may also indirectly influence the cardiovascular health when you lead to severe dehydration or excessive loss of pressure.
Dehydration can affect your stress?
Yes.
Severe vomiting or diarrhea, persistent, may lead to the loss of fluids.
It can lower your blood pressure and increase your risk of dizziness, fainting, and kidney problems.
People also use water pills (diuretics) or medicines that pressure may need extra attention during episodes of significant fluid loss.
For this reason, the effects of the gastro-intestinal intense, not to be missed simply because a person is losing weight.
How to keep track of the cardiovascular system during the treatment.
The follow-up depends on the profile of the individual, but may include:
- blood pressure;
- and weight, and waist;
- blood sugar (glucose);
- hemoglobin glicada;
- low density lipoprotein cholesterol;
- LD;
- tg;
- renal function.
- symptoms of cardiovascular diseases;
- physical activity.
For some people, additional testing may be required.
The idea is not to develop a broader understanding of the excess, but to keep track of all of the factors that actually influence the cardiovascular health according to the medical record.
What the signs need support?
Look for support in the face of problems such as:
- pain or pressure in your chest;
- shortness of breath important.
- light-headed;
- weakness of a sudden on one side of the body;
- difficulty of a sudden, to speak, and
- neurological sudden-onset;
- palpitations, intense, and accompanied the ill-being.
These signs should not be automatically assigned to the Tirzepatida.
Emergency cardiovascular disease in need of immediate evaluation.
Tirzepatida is a medicine for the heart”?
It's not the best way to describe the product.
In Brazil, the Tirzepatida has signs related to type 2 diabetes and chronic, of the weight of the criteria are approved by the Fda.
What the research shows is that it can improve many of the risk factors, and at the SURPASS-CVOT, tested cardio is not less than the dulaglutida in people with type 2 diabetes, and atherosclerotic disease.
Therefore, it is more correct to speak of it in evidence that are relevant to the cardiovascular health in the present Tirzepatida as a medicine is uniquely well-respected.
Frequently asked questions
Tirzepatida it's good for the heart.
It improves a number of factors that are related to the risk of cardiovascular disease, such as weight, blood sugar, and blood pressure. The SURPASS-CVOT, it was no less than the dulaglutida for cardiovascular death, heart attack or STROKE in people with type 2 diabetes and heart disease is established.
Tirzepatida reduce heart attacks?
The SURPASS-CVOT did not demonstrate superiority of the statistical office of the Tirzepatida on dulaglutida on the outcome combination of cardiovascular death, heart attack or STROKE.
Your blood pressure can you lower?
Yes. Studies in people with obesity, they observed a reduction in blood pressure, including monitoring, for 24 hours.
Do I know my remedy for stress?
Not on their own. If the pressure is significantly lower, and the treatment should be re-evaluated by the professional in charge.
Tirzepatida reduce cholesterol?
It can improve certain parameters of lipids, especially triglycerides, and other factors cardiometabólicos, but it does not replace treatment, specific for low density lipoprotein.
Can't stop the statin?
Don't do it on their own. The need for statin depends on the risk of cardiovascular disease and should be assessed separately.
Lose weight with the help of the heart.
To reduce excess weight, it can improve the pressure, glucose, visceral fat, and the various factors that cardiometabólicos.
Conclusion
The evidence of Tirzepatida and cardiovascular health they were the most complete, with the publication of the SURPASS-CVOT.
In the more than 13-thousand people with type 2 diabetes and atherosclerotic cardiovascular disease, Tirzepatida was not lower than that of the dulaglutida the outcome combination of cardiovascular death, heart attack or STROKE.
The main event has occurred in the 12,2% of the participants, and are treated with Tirzepatida and 13,1% for those who have received dulaglutida.
The study did not demonstrate superiority to statistics, so it is not correct to say that the Tirzepatida reduces cardiovascular events more than dulaglutida.
At the same time, the study of obesity showed an improvement of blood pressure, weight, and the different factors that cardiometabólicos.
These changes will be relevant to cardiovascular healthespecially, in people with obesity, diabetes and multiple risk factors.
But the treatment is not substitutes for the control of LDL cholesterol, blood pressure, physical activity, diet, smoking cessation, and other concerns.
The best way to interpret the data it is looking for the Tirzepatida as a tool to improve the various components of the risk cardiometabólico within a broader strategy of care.
References
- Nicholls SJ, et al. — Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. The New England Journal of Medicine, 2025.
- de Lemos JA, et al. — Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With a BMI of ≥27 kg/m2). Hypertension, 2024.
- Hankosky, ER, et, al. — Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight.
- Jastreboff AM, et al. — Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine.
- The brazilian National agency of Sanitary Surveillance (Anvisa) — Mounjaro® (tirzepatida): re-appointment.
Content is up-to-date in August, 2026.
Read On To Find Out
Nausea, with tirzepatida: is it normal?
Tirzepatida the cause of indigestion? To understand the onset of discomfort after eating
Tirzepatida gives you diarrhea? Find out why it happens and what to do
